Dr. Pishvaian on the Future of Entrectinib in Pancreatic Cancer
It is important to identify which patients should receive this regimen, explains Pishvaian. There is a lot of controversy about whether molecular profiling should be done on patients with pancreatic cancer. Read more . . .